Legal & General Group Plc Has $2.78 Billion Holdings in AbbVie Inc. $ABBV

Legal & General Group Plc grew its holdings in AbbVie Inc. (NYSE:ABBV) by 4.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,004,084 shares of the company’s stock after purchasing an additional 493,420 shares during the period. AbbVie comprises 0.6% of Legal & General Group Plc’s portfolio, making the stock its 19th largest holding. Legal & General Group Plc owned about 0.68% of AbbVie worth $2,779,426,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in AbbVie by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after buying an additional 448,554 shares in the last quarter. Geode Capital Management LLC boosted its position in AbbVie by 2.4% during the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock valued at $7,240,169,000 after purchasing an additional 924,761 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in AbbVie by 6.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after purchasing an additional 1,517,222 shares in the last quarter. Norges Bank acquired a new position in AbbVie in the 2nd quarter worth about $4,288,200,000. Finally, Raymond James Financial Inc. increased its position in AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after purchasing an additional 2,753,312 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $227.75 on Tuesday. The stock has a market capitalization of $402.70 billion, a P/E ratio of 96.50, a P/E/G ratio of 0.80 and a beta of 0.34. The business has a 50-day moving average of $224.66 and a two-hundred day moving average of $224.33. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the prior year, the firm posted $2.16 EPS. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Insider Buying and Selling

In related news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.08% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Phase 1 ABBV‑295 (long‑acting amylin analog) showed clinically meaningful weight loss (~7.8–9.8% at week 12/13) with favorable tolerability, supporting continued development as a non‑incretin obesity option. AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
• Positive Sentiment: Positive Phase 3 AFFIRM topline results for risankizumab (SKYRIZI) in Crohn’s disease point to label expansion and incremental sales upside for an already commercialized franchise. AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease
• Positive Sentiment: Analyst support: J.P. Morgan reiterated a Buy rating, which reinforces investor confidence in AbbVie’s mix of cash flow, dividend, and pipeline optionality. J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
• Positive Sentiment: Industry coverage notes ABBV‑295’s competitive profile vs. GLP‑1/GIP approaches, which could drive differentiated positioning if later‑stage data hold up. AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
• Neutral Sentiment: Analyst / media attention (Zacks, Yahoo) is elevating interest in ABBV as a momentum/dividend name, but these are background supports rather than immediate catalysts. Here’s Why AbbVie (ABBV) is a Strong Momentum Stock
• Neutral Sentiment: Broader write‑ups synthesize recent trial updates into AbbVie’s valuation/growth outlook — useful context but not a single-day catalyst. AbbVie Trial Updates Add Context To Valuation And Growth Outlook
• Negative Sentiment: Despite positive ABBV‑295 numbers, shares fell after the readout — investors may be disappointed relative to expectations versus GLP‑1/GIP therapies or are focusing on pathway uncertainty and commercialization risk. AbbVie’s Early Obesity Drug Data Shows Up To 10% Weight Loss
• Negative Sentiment: ICER will review AbbVie’s Parkinson’s drug — a health‑economics review can lead to pricing/reimbursement pressures if cost‑effectiveness is questioned. ICER to review AbbVie’s Parkinson’s disease drug
• Negative Sentiment: Corporate/financial items: an SVP sold about $1.22M of stock and AbbVie has tied roughly $350M to the amylin program — insider selling and program commitments can be read as modest near‑term negatives for sentiment or cash deployment. AbbVie (NYSE:ABBV) SVP Sells $1,221,518.80 in Stock AbbVie ties $350m amylin bet to almost 10% weight loss after 12 weeks

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Morgan Stanley raised their price target on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Berenberg Bank set a $275.00 price objective on AbbVie in a report on Tuesday, January 20th. Piper Sandler raised their price objective on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Barclays started coverage on shares of AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 target price for the company. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.